Stem Cell Therapeutic and Research Reauthorization Act of 2025

U.S. Congress · HR5160 · Floor

Progression

Timing in context

Primary sponsor's contributions received (same period)

Adjacency in time is shown for context; it is not evidence of cause. Funded ≠ false — see the methodology.

What the bill says

HR5160 · U.S. Congress · Floor

Introduced 2025-09-04. Latest action: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.

View on Congress.gov →

Summary (plain-language)

Stem Cell Therapeutic and Research Reauthorization Act of 2025 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Sponsors

Text versions

  • Introduced in House — 2025-09-04 — XML
  • Reported in House — 2026-07-02 — XML
  • Engrossed in House — 2026-07-20 — XML
  • Placed on Calendar Senate — 2026-07-21 — XML

What analysts say

Committee reports

  • H. Rept. 119-724
    Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Off…

    Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available.

    CBO cost estimate from the committee report (public domain).

What politicians say

No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.

Action History

DateAction
2026-07-21Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
2026-07-20Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
2026-07-20Considered under suspension of the rules. (consideration: CR H4642-4643)
2026-07-20DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
2026-07-20Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
2026-07-20On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
2026-07-20Motion to reconsider laid on the table Agreed to without objection.
2026-07-02Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
2026-07-02Placed on the Union Calendar, Calendar No. 629.
2026-05-21Committee Consideration and Mark-up Session Held
2026-05-21Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
2026-05-13Subcommittee Consideration and Mark-up Session Held
2026-05-13Forwarded by Subcommittee to Full Committee by Voice Vote.
2025-09-04Introduced in House
2025-09-04Referred to the House Committee on Energy and Commerce.
2025-09-04Referred to the Subcommittee on Health.

← Back to legislation